Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.090
-0.030 (-1.42%)
Aug 6, 2026, 11:56 AM EDT - Market open
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
362.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 51.00M |
| Zentalis Pharmaceuticals | 26.87M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
| Vicore Pharma Holding AB | 370.61K |
PALI News
- 5 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 14 days ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly
- 24 days ago - Palisade Bio management to meet with Piper Sandler - TheFly
- 27 days ago - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 weeks ago - Palisade Bio receives FDA clearance to start ulcerative colitis study - TheFly
- 5 weeks ago - Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis - GlobeNewsWire
- 2 months ago - Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewsWire
- 2 months ago - Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium - GlobeNewsWire